Metformin Hydrochloride belongs to a biguanide class of oral antidiabetic drugs. It decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity. Unlike sulfonylureas, Metformin Hydrochloride does not produce hypoglycemia. It is the drug of first choice in obese patients. Metformin Hydrochloride, as monotherapy, is indicated as an adjunct to diet to lower blood glucose in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia can not be satisfactorily managed on diet alone. Metformin Hydrochloride may be used concomitantly with a sulfonylurea when diet and Metformin Hydrochloride or sulfonylureas alone do not result in adequate glycemic control.